Ruxolitinib significantly decreased these cytokine concentrations in CD3/28 antibody-treated PBMC ethnicities as well, along with decrease in IL-10
Ruxolitinib significantly decreased these cytokine concentrations in CD3/28 antibody-treated PBMC ethnicities as well, along with decrease in IL-10. and methods